BEGIN:VCALENDAR
PRODID:-//Microsoft Corporation//Outlook 16.0 MIMEDIR//EN
VERSION:2.0
METHOD:REQUEST
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VTIMEZONE
TZID:W. Europe Standard Time
BEGIN:STANDARD
DTSTART:16011028T030000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:16010325T020000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
ATTENDEE;CN="Møterom E-helse 4316 Cisco - 15 pl";CUTYPE=RESOURCE;ROLE=NON-
	PARTICIPANT;RSVP=TRUE:mailto:Moterom.e-helse.4316.-.10pl@ehelse.no
ATTENDEE;CN="Espen Stranger Seland - Helsedirektoratet (espen.stranger.sela
	nd@ehelse.no)";RSVP=TRUE:mailto:espen.stranger.seland@ehelse.no
ATTENDEE;CN=MICHAL.CERMAK@NHN.NO;RSVP=TRUE:mailto:MICHAL.CERMAK@NHN.NO
ATTENDEE;CN="Øyvind Aassve";RSVP=TRUE:mailto:oeyaas@sykehuspartner.no
ATTENDEE;CN="Dag Hammer";RSVP=TRUE:mailto:Dag.Hammer@nhn.no
ATTENDEE;CN="Ole Martin Winnem (Innleid)";RSVP=TRUE:mailto:ole.martin.winne
	m@nhn.no
ATTENDEE;CN=info@hl7.no;ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:info@hl7.no
ATTENDEE;CN="Andersen, Ronny Heitmann";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailt
	o:ronny.heitmann.andersen@helse-vest-ikt.no
ATTENDEE;CN="Reite, Toril Ormberg";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:to
	ril.ormberg.reite@helse-vest-ikt.no
ATTENDEE;CN="Jon Aarbakke";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:ja@promis.
	no
ATTENDEE;CN="Bjørn Fjukstad";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:bfj@dip
	s.no
ATTENDEE;CN="Ciprian-Virgil Gerstenberger";ROLE=OPT-PARTICIPANT;RSVP=TRUE:m
	ailto:Ciprian.Gerstenberger@ehealthresearch.no
ATTENDEE;CN="Kristiansen, Svein Gunnar";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mail
	to:svein.gunnar.kristiansen@helse-vest-ikt.no
ATTENDEE;CN="Bjørnsen-Hagen, Eilev";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:
	Eilev.Hagen@hemit.no
ATTENDEE;CN="Adam Kover";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:adam.kover@f
	elleskatalogen.no
ATTENDEE;CN="Svensøy, Jarle";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:jarle.s
	vensoy@capgemini.com
ATTENDEE;CN="Eirik Myklebost";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:eirikm@
	aboveit.no
ATTENDEE;CN="Armann Helgason";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:Armann.
	Helgason@tietoevry.com
ATTENDEE;CN="Henrik Næss";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:Henrik.Nae
	ss@ehelse.no
ATTENDEE;CN="Bjørn Næss";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:bna@dips.n
	o
ATTENDEE;CN="Linn Brandt";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:Linn.Brandt
	@ehelse.no
ATTENDEE;CN="Helge Skjønberg";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:Helge.
	Skjonberg@sykehuspartner.no
ATTENDEE;CN="Andy Harrison";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:andy.harr
	ison@egde.no
ATTENDEE;CN="Jorn Agnar Solheim";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:jorn
	agnar.solheim@tietoevry.com
ATTENDEE;CN="Mikal Reed";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:mr@konik.no
ATTENDEE;CN="Holm, Roar Jæger";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:roar.
	jeger.holm@helse-vest-ikt.no
ATTENDEE;CN="Bente Cecilie By Jansen";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto
	:bente.jansen@felleskatalogen.no
ATTENDEE;CN="Jørn Sikkerbøl";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:Jorn.S
	ikkerbol@ehelse.no
ATTENDEE;CN="Jan Robert Johannessen (FLS)";ROLE=OPT-PARTICIPANT;RSVP=TRUE:m
	ailto:Johannessen@Fastlegeservice.no
ATTENDEE;CN="Øystein Nytrø";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:nytroe@
	ntnu.no
ATTENDEE;CN="Sæle, Line Andreassen";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:
	LineAndreassen.Saele@fhi.no
ATTENDEE;CN="Lars Kristian Roland";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:la
	rs.kristian.roland@ks.no
ATTENDEE;CN="Nicolas Øyane";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:nicolas.
	oyane@skilnet.no
ATTENDEE;CN="Mario G. Hyland (AEGIS.net)";ROLE=OPT-PARTICIPANT;RSVP=TRUE:ma
	ilto:mario.hyland@aegis.net
ATTENDEE;CN="Håvard Moås";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:hmo@dips.
	no
ATTENDEE;CN="Elin Høyvik Kindingstad";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailt
	o:Elin.Hoyvik.Kindingstad@ehelse.no
ATTENDEE;CN="John Harald Sevaldsen";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:j
	hs@dips.no
ATTENDEE;CN="Ida Iren Eriksen";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:iie@di
	ps.no
ATTENDEE;CN="Tore Hugo Bjerke";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:tohbje
	@sykehuspartner.no
ATTENDEE;CN="Sassan Sokhan-Sanj";ROLE=OPT-PARTICIPANT;RSVP=TRUE:invalid:nom
	ail
ATTENDEE;CN="Anita Lorck";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:Anita.Lorck
	@ehelse.no
ATTENDEE;CN="Anders Stormo";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:anders@he
	lseapps.no
ATTENDEE;CN="Johan Gustav Bellika";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:Jo
	han.Gustav.Bellika@ehealthresearch.no
ATTENDEE;CN="Rune Brækken";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:runebr@sy
	kehuspartner.no
ATTENDEE;CN="Øivind Riis";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:Oivind.Rii
	s@so-hf.no
ATTENDEE;CN="Frank Alexander Berger";ROLE=OPT-PARTICIPANT;RSVP=TRUE:mailto:
	uxbfra@sykehuspartner.no
CLASS:PUBLIC
CREATED:20220111T061807Z
DESCRIPTION:Velkommen til det tiende møtet i FHIR fagforum\n\nTema: Legemi
	dler og medikasjon\n\nFHIR fagforum (FFF) er et åpent forum om bruk og im
	plementering av HL7 FHIR i Norge. FFF er åpent for alle.\n\nAgenda og ann
	en informasjon legges ut på: https://hl7norway.github.io/best-practice/do
	cs/FHIR-faglig-forum/\n\n_________________________________________________
	_______________________________ \n\nMicrosoft Teams-møte \n\nBli med fra 
	datamaskin eller mobilapp \n\nKlikk her for å delta i møtet <https://tea
	ms.microsoft.com/l/meetup-join/19%3ameeting_MTNiNzZlOWMtMGMwZi00Y2ZlLWIzYm
	UtZDFhNWUwYmI5NDMw%40thread.v2/0?context=%7b%22Tid%22%3a%221f8fc8cc-99b4-4
	10a-95fa-286dd143b04d%22%2c%22Oid%22%3a%22a216d89f-4166-4e08-9907-183e70a2
	a420%22%7d>  \n\nFinn ut mer <https://aka.ms/JoinTeamsMeeting>  | Møtealt
	ernativer <https://teams.microsoft.com/meetingOptions/?organizerId=a216d89
	f-4166-4e08-9907-183e70a2a420&tenantId=1f8fc8cc-99b4-410a-95fa-286dd143b04
	d&threadId=19_meeting_MTNiNzZlOWMtMGMwZi00Y2ZlLWIzYmUtZDFhNWUwYmI5NDMw@thr
	ead.v2&messageId=0&language=nb-NO>  \n\n__________________________________
	______________________________________________ \n\n \n\n
DTEND;TZID="W. Europe Standard Time":20220202T150000
DTSTAMP:20220105T081709Z
DTSTART;TZID="W. Europe Standard Time":20220202T130000
LAST-MODIFIED:20220111T061807Z
LOCATION:Møterom E-helse 4316 Cisco - 15 pl
ORGANIZER;CN="Thomas Tveit Rosenlund":mailto:Thomas.Tveit.Rosenlund@ehelse.
	no
PRIORITY:5
SEQUENCE:2
SUMMARY;LANGUAGE=no:FHIR fagforum #10
TRANSP:OPAQUE
UID:040000008200E00074C5B7101A82E00800000000F05DDF7083E6D701000000000000000
	010000000F600FE8106CD3242B6EAEB88934E7224
X-ALT-DESC;FMTTYPE=text/html:<html xmlns:v="urn:schemas-microsoft-com:vml" 
	xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-mic
	rosoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/
	12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta name=Generato
	r content="Microsoft Word 15 (filtered medium)"><style><!--\n/* Font Defin
	itions */\n@font-face\n	{font-family:"Cambria Math"\;\n	panose-1:2 4 5 3 5
	 4 6 3 2 4\;}\n@font-face\n	{font-family:Calibri\;\n	panose-1:2 15 5 2 2 2
	 4 3 2 4\;}\n@font-face\n	{font-family:"Segoe UI"\;\n	panose-1:2 11 5 2 4 
	2 4 2 2 3\;}\n@font-face\n	{font-family:"Segoe UI Semibold"\;\n	panose-1:2
	 11 7 2 4 2 4 2 2 3\;}\n/* Style Definitions */\np.MsoNormal\, li.MsoNorma
	l\, div.MsoNormal\n	{margin:0cm\;\n	font-size:11.0pt\;\n	font-family:"Cali
	bri"\,sans-serif\;\n	mso-fareast-language:EN-US\;}\na:link\, span.MsoHyper
	link\n	{mso-style-priority:99\;\n	color:#0563C1\;\n	text-decoration:underl
	ine\;}\nspan.EpostStil18\n	{mso-style-type:personal-compose\;\n	font-famil
	y:"Calibri"\,sans-serif\;\n	color:windowtext\;}\n.MsoChpDefault\n	{mso-sty
	le-type:export-only\;\n	font-size:10.0pt\;}\n@page WordSection1\n	{size:61
	2.0pt 792.0pt\;\n	margin:70.85pt 70.85pt 70.85pt 70.85pt\;}\ndiv.WordSecti
	on1\n	{page:WordSection1\;}\n--></style><!--[if gte mso 9]><xml>\n<o:shape
	defaults v:ext="edit" spidmax="1026" />\n</xml><![endif]--><!--[if gte mso
	 9]><xml>\n<o:shapelayout v:ext="edit">\n<o:idmap v:ext="edit" data="1" />
	\n</o:shapelayout></xml><![endif]--></head><body lang=NO-BOK link="#0563C1
	" vlink="#954F72" style='word-wrap:break-word'><div class=WordSection1><di
	v><p><span style='color:black'>Velkommen til det tiende&nbsp\;møtet i FHI
	R fagforum<o:p></o:p></span></p><p><span style='color:black'>Tema: Legemid
	ler og medikasjon<o:p></o:p></span></p><p><span style='color:black'>FHIR f
	agforum (FFF) er et åpent forum om bruk og implementering av HL7 FHIR i N
	orge. FFF er åpent for alle.</span><span style='font-size:12.0pt\;color:b
	lack'><o:p></o:p></span></p><p><span style='color:black'>Agenda og annen i
	nformasjon legges ut på:&nbsp\;<a href="https://hl7norway.github.io/best-
	practice/docs/FHIR-faglig-forum/">https://hl7norway.github.io/best-practic
	e/docs/FHIR-faglig-forum/</a></span><span style='font-size:12.0pt\;color:b
	lack'><o:p></o:p></span></p><p class=MsoNormal><span style='color:#5F5F5F'
	>_________________________________________________________________________
	_______</span> <o:p></o:p></p></div><div><div style='margin-top:18.0pt\;ma
	rgin-bottom:15.0pt'><p class=MsoNormal><span style='font-size:18.0pt\;font
	-family:"Segoe UI"\,sans-serif\;color:#252424'>Microsoft Teams-møte</span
	><span style='font-family:"Segoe UI"\,sans-serif\;color:#252424'> <o:p></o
	:p></span></p></div><div style='margin-bottom:15.0pt'><div><p class=MsoNor
	mal><b><span style='font-size:10.5pt\;font-family:"Segoe UI"\,sans-serif\;
	color:#252424'>Bli med fra datamaskin eller mobilapp</span></b><b><span st
	yle='font-family:"Segoe UI"\,sans-serif\;color:#252424'> <o:p></o:p></span
	></b></p></div><p class=MsoNormal><span style='font-family:"Segoe UI"\,san
	s-serif\;color:#252424'><a href="https://teams.microsoft.com/l/meetup-join
	/19%3ameeting_MTNiNzZlOWMtMGMwZi00Y2ZlLWIzYmUtZDFhNWUwYmI5NDMw%40thread.v2
	/0?context=%7b%22Tid%22%3a%221f8fc8cc-99b4-410a-95fa-286dd143b04d%22%2c%22
	Oid%22%3a%22a216d89f-4166-4e08-9907-183e70a2a420%22%7d" target="_blank"><s
	pan style='font-size:10.5pt\;font-family:"Segoe UI Semibold"\,sans-serif\;
	color:#6264A7'>Klikk her for å delta i møtet</span></a> <o:p></o:p></spa
	n></p></div><div style='margin-top:15.0pt\;margin-bottom:18.0pt'><p class=
	MsoNormal><span style='font-family:"Segoe UI"\,sans-serif\;color:#252424'>
	<a href="https://aka.ms/JoinTeamsMeeting" target="_blank"><span style='fon
	t-size:10.5pt\;color:#6264A7'>Finn ut mer</span></a> | <a href="https://te
	ams.microsoft.com/meetingOptions/?organizerId=a216d89f-4166-4e08-9907-183e
	70a2a420&amp\;tenantId=1f8fc8cc-99b4-410a-95fa-286dd143b04d&amp\;threadId=
	19_meeting_MTNiNzZlOWMtMGMwZi00Y2ZlLWIzYmUtZDFhNWUwYmI5NDMw@thread.v2&amp\
	;messageId=0&amp\;language=nb-NO" target="_blank"><span style='font-size:1
	0.5pt\;color:#6264A7'>Møtealternativer</span></a> <o:p></o:p></span></p><
	/div></div><div><p class=MsoNormal><span style='color:#5F5F5F'>___________
	_____________________________________________________________________</spa
	n> <o:p></o:p></p></div><p class=MsoNormal><o:p>&nbsp\;</o:p></p></div></b
	ody></html>
X-MICROSOFT-CDO-BUSYSTATUS:BUSY
X-MICROSOFT-CDO-IMPORTANCE:1
X-MICROSOFT-DISALLOW-COUNTER:FALSE
X-MS-OLK-APPTLASTSEQUENCE:2
X-MS-OLK-APPTSEQTIME:20220105T081709Z
X-MS-OLK-AUTOFILLLOCATION:TRUE
X-MS-OLK-CONFTYPE:0
BEGIN:VALARM
TRIGGER:-PT15M
ACTION:DISPLAY
DESCRIPTION:Reminder
END:VALARM
END:VEVENT
END:VCALENDAR
